Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
In November 2011, the GAVI Alliance made the decision to add HPV vaccine as one of the new vaccines for which countries eligible for its funding (less than $1520 per capita income) could apply to receive support for national HPV vaccination, provided they could demonstrate the ability to deliver HPV...
Main Authors: | Ann Levin, Susan A Wang, Carol Levin, Vivien Tsu, Raymond Hutubessy |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4072768?pdf=render |
Similar Items
-
Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts
by: Jit Mark, et al.
Published: (2013-01-01) -
Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries
by: Jessica Ochalek, et al.
Published: (2020-10-01) -
Gavi HPV Programs: Application to Implementation
by: Celina M. Hanson, et al.
Published: (2015-05-01) -
Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects.
by: Siobhan Botwright, et al.
Published: (2017-01-01) -
Assessing vaccine introduction and uptake timelines in Gavi-supported countries: are introduction timelines accelerating across vaccine delivery platforms?
by: Karuna Luthra, et al.
Published: (2021-05-01)